Home

Insights

PE

Nectar Lifescience Ltd P/E Ratio

Nectar Lifescience Ltd P/E Ratio

download
stocks purchased

₹ 0.2 Cr

Volume transacted

stocks purchased

74.1 K

stocks traded

Last Updated time: 13 Jul 9.00 AM

Image

Nectar Lifescience Ltd

NSE: NECLIFE

PE

135.1

Last updated : 13 Jul 9.00 AM

Key Highlights

    The P/E Ratio of Nectar Lifescience Ltd is 135.1 as of 13 Jul 9.00 AM .a1#The P/E Ratio of Nectar Lifescience Ltd changed from 8.1 on March 2019 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years. a1#The Latest Trading Price of Nectar Lifescience Ltd is ₹ 29.73 as of 12 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.7. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Pharmaceuticals industry is 37.5. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Nectar Lifescience Ltd changed from ₹ 383.49 crore on March 2019 to ₹ 355.68 crore on March 2023 . This represents a CAGR of -1.49% over 5 years. a1#The Revenue of Nectar Lifescience Ltd changed from ₹ 403.39 crore to ₹ 442.84 crore over 8 quarters. This represents a CAGR of 4.78% a1#The EBITDA of Nectar Lifescience Ltd changed from ₹ 42.17 crore to ₹ 49.97 crore over 8 quarters. This represents a CAGR of 8.86% a1#The Net Pr of Nectar Lifescience Ltd changed from ₹ 3.9 crore to ₹ 0.59 crore over 8 quarters. This represents a CAGR of -61.11% a1#The Dividend Payout of Nectar Lifescience Ltd changed from 2.37 % on March 2019 to 0 % on March 2023 . This represents a CAGR of -100.00% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Nectar Lifescience Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Nectar Lifescience Ltd

Period
Mar '198.1
Mar '207
Mar '210
Mar '2221.5
Mar '230

Company Fundamentals for Nectar Lifescience Ltd

Market Cap

666 Cr

EPS

0.2

P/E Ratio (TTM) *

135.1

P/B Ratio (TTM) *

0.6

Day’s High

30.18

Day’s Low

29.5

DTE *

0.6

ROE *

0.5

52 Week High

45.7

52 Week Low

21.05

ROCE *

6.2

* All values are consolidated

Last Updated time: 13 Jul 9.00 AM

* All values are consolidated

Last Updated time: 13 Jul 9.00 AM

Image

Nectar Lifescience Ltd

NSE: NECLIFE

PRICE

29.73

-0.33 (-1.10%)

stock direction

Last updated : 12 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Nectar Lifescience Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value of Nectar Lifescience Ltd

Market Value

667

-0.5 X

Value addition

Asset Value

1,386

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Nectar Lifescience Ltd135666
Sun Pharmaceuticals Industries Ltd37378,675
Cipla Ltd28122,093
Divis Laboratories Ltd75120,480
Zydus Lifesciences Ltd30118,217
Dr Reddys Laboratories Ltd20112,137

Key Valuation Metric of Nectar Lifescience Ltd

Earnings

5 Cr

135.1 X

PE Ratio

Market Cap

₹666.73Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

5 Cr

135.1 X

PE Ratio

Market Cap

₹666.73Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Nectar Lifescience Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Nectar Lifescience Ltd

Period
Mar '19383
Mar '20222
Mar '21417
Mar '22539
Mar '23356

* All values are a in crore

×

Historical Revenue of Nectar Lifescience Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Nectar Lifescience Ltd

Period
Jun '22403
Sep '22399
Dec '22357
Mar '23407
Jun '23395
Sep '23409
Dec '23453
Mar '24443

* All values are a in crore

×

Historical EBITDA of Nectar Lifescience Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Nectar Lifescience Ltd

Period
Jun '2242
Sep '223
Dec '2215
Mar '2336
Jun '2336
Sep '2337
Dec '2343
Mar '2450

* All values are a in crore

×

Historical Net Profit of Nectar Lifescience Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Nectar Lifescience Ltd

Period
Jun '224
Sep '22-22
Dec '22-9
Mar '234
Jun '232
Sep '231
Dec '232
Mar '241

* All values are a in crore

×

Historical Dividend Payout of Nectar Lifescience Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Nectar Lifescience Ltd

Period
Mar '192
Mar '204
Mar '210
Mar '220
Mar '230

* All values are a in %

About Nectar Lifescience Ltd

About Nectar Lifescience Ltd

    Nectar Lifesciences Ltd (NLL or NECLIFE) is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products. The company manufactures Cephalosporin Active pharmaceutical ingredients, finished dosage forms, Phytochemicals, and hard gelatin capsules at their facilities spread across three Indian states of Punjab, Himachal Pradesh and Jammu. They have developed sustainable production systems to manufacture high quality intermediates and APIs to meet the diverse requirements of their customer base in India and over 90 countries worldwide. The company's business operations are primarily concentrated on manufacturing and marketing of oral and sterile cephalosporins, phytochemicals and allied products. They manufacture and sell a range of cephalosporins and phytochemicals. They are also engaged in contract manufacturing of API's for pharmaceutical players. Nectar Lifesciences Ltd was incorporated on June 27, 1995 as a public limited company with the name Surya Medicare Ltd. The company was established pursuant to a financial collaboration agreement between the Promoters and Punjab State Industrial Development Corporation. In April 1997, the company commenced business with the commercial production of Oral Bulk Drugs at their manufacturing facility located in the B Category zone of Punjab. In March 1998, they started the production of Sterile Bulk Drugs. In the year 1999, they added the formulation facilities by setting up a vial filing section for Crystalline Sterile Bulk Drugs. In the year 2000, the company undertook an expansion by increasing the installed capacity Crystalline Sterile Bulk Drugs from 406 MT to 810 MT. In the year 2001, they also installed one Crystalline section of 65 MT per annum, which commenced production in October 2001. In the year 2002, the company undertook another expansion programme increasing the production capacity for Cephalosporin Sterile. In October 18, 2002, they incorporated Chempharma (Pvt) Ltd as a wholly-owned subsidiary company in Sri Lanka to manufacture API intermediaries. In the year 2003, the company commenced modernization / expansion plan for increasing our presence in the Cephalosporins segment. In April 2003, the company bought back the entire shareholding of PSIDC at a price of Rs 16.47 per share under the One Time Settlement policy announced by Government of Punjab - Industrial Policy, 2003. In the year 2004, the company started production in a portion of the new Cephalosporins plant. In March 26, 2004, the company changed their name from Surya Medicare Ltd to Nectar Lifesciences Ltd. During the year 2006-07, the company commissioned a state-of-the-art facility dedicated to the non-antibiotic therapeutic segment in compliance with stringent US-FDA and EDQM guidelines. The company established a state-of-the-art mint derivatives plant, initiating its business activity into the phytochemicals arena. They also up a menthol flakes facilities at SIDCO Industrial Complex, Jammu to add to the requisite business activity with all the locational benefits to the industry in J&K. They commissioned a unit in Derabassi to process menthol into powder and crystal forms The company also established an Empty Hard Gelatin Capsule unit at Baddi, Himachal Pradesh referred to as Unit VII which commenced production with effect from April 2007. In April 2008, they set up a state-of-the-art facility, Unit X at Derabassi, which commissioned on April 17, 2008. During the year 2008-09, the company increased the production capacity of Bulk Drug & Sterile from 425 MT to 650 MT. Also, they increased the production capacity of Phytochemicals - Menthol from 6000 MT to 7600 MT. They launched 30 formulation brands (P2P). Also, they established a fully-owned formulation R&D centre in Derabassi dedicated to non-cephalosporins related developments like oncology, anti-diabetes, cardiovascular system, female healthcare and anti-HIV. During the year 2009-10, the company increased the production capacity of Bulk Drug & Sterile from 650 MT to 1600 MT. Also, they launched the diagnostic division during the year. During FY 2010-11, M/s Nectar Capital Limited was incorporated in Mauritius and M/s Nectar Lifesciences UK Limited, was incorporated in United Kingdom. Nectar Lifesciences US, LLC in United States was also incorporated during year 2014-15, which commenced the business operations of trading in pharmeceutical products. In March 2011, the company received approval from the Japanese MOH for their product, Cefuroxime Axetil. The company incorporated a WOS namely NECLIFE PT, UNIPESSOAL LDA in Portugal on July 11, 2019 to takeover MA from Nectar Lifesciences UK Limited. Two new innovative products in EHGC - menthol capsules (Nexxicap MintyTM) and pearl capsule (Nexxicap PearlTM) were launched in 2019-20.

Nectar Lifescience Ltd News Hub

News

Nectar Lifescience announces board meeting date

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 15 May ...

Read more

08 May 202415:46

News

Nectar Lifescience to conduct board meeting

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 Febr...

Read more

02 Feb 202410:53

News

Nectar Lifescience announces board meeting date

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 10 Nove...

Read more

07 Nov 202316:14

News

Nectar Lifescience to announce Quarterly Result

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 Augu...

Read more

09 Aug 202315:33

News

Nectar Lifescience schedules AGM

Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be ...

Read more

29 May 202315:03

News

Nectar Lifescience to table results

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 26 May ...

Read more

23 May 202314:19

Product Composition by Percentage (Revenue)

FAQs for PE of Nectar Lifescience Ltd

What is Nectar Lifescience Ltd current share price?

The current market price of Nectar Lifescience Ltd as of July 13, 2024 is ₹29.73.

What is Nectar Lifescience Ltd's market cap?

Nectar Lifescience Ltd's market capitalisation stood at ₹666 Cr as of July 13, 2024

What are Nectar Lifescience Ltd's total net assets?

According to Nectar Lifescience Ltd's most recent financial filings, the company's net assets total ₹1386.0 Cr.

Is Nectar Lifescience Ltd making a profit or loss?

Nectar Lifescience Ltd's net Profit as of July 13, 2024 is close to ₹5 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199